Description: Indexed universal life (IUL) continues to be the most popular universal life (UL) product with sales reaching $1B in Q4 2023, according to LIMRA. There is little long-term experience for IUL and many companies value and model IUL just like UL, but there are material potential differences that need to be considered for valuation and projection purposes.

Description: Driver-based forecasting is a powerful tool to predict and estimate future outcomes. In recent years, driver-based forecasting has gained significant attention as a technique for actuaries to forecast the financial performance of insurance companies. Often there can be frustration around the ability to use forecasts to manage the business. However the objective of a driver-based forecast is to break down historic and projected movement based on the key drivers which impact the results. The key is to understand what the key drivers are on forecasts and what is the relative level of impact and influence we have on the drivers. Listen in on a discussion on the core principles of driver-based forecasting, including how to identify key drivers, collect accurate data, and leverage the latest technology to generate forecasts that traditional models can't match. Explore with us the various driver-based models and how actuaries can leverage them to enhance their decision-making capabilities. Then join the conversation about the challenges actuaries face when implementing this technique and how to mitigate these problems.

Description: The rapid and persistent rise in rates has increased many insurer's concerns around liquidity, disintermediation, and overall ALM risk management. Learn an overview of ALM, including the goals and reasons for performing it, common approaches, and real-world examples of common pit falls and mistakes that have been made in the industry. Explore the differences in approaches, and the pros and cons of these various approaches.Learn about the importance of understanding the ALM approach, with clearly defined strategic objectives. Additionally,discover an understanding of the value to both managing risk and optimizing enterprise value. Come away with a deep appreciation for the value that a well-constructed ALM program can bring to valuation/capital planning/asset adequacy testing/pricing (life and annuity).

Description: A panel of actuaries and investment experts share their experience with the AG53 requirements for Asset Adequacy Testing. Discuss challenging areas in the inaugural year of the consideration of complex assets as well as discuss potential areas of future regulatory expectations

Description: With large public filers having adopted LDTI in 2023, company practices are continuing to evolve as it relates to experience monitoring, assumption unlocking, as well as both internal and external communication and disclosures related to assumptions. In this diverse session featuring representatives from both insurance companies as well as industry analysts, we'll explore how companies approach emerging experience in a given year through a case study approach. The moderator will explore various topics such as off-cycle experience monitoring, experience outliers, simplifications and approximations, and materiality considerations. Each 'what-if' scenario will start with a prompt from the moderator, discussion among the industry panelists as to how they would approach the situation within their own organization, followed by commentary from the analysts as to how they might expect companies to respond in each case. Audience participation will be encouraged to explore potential alternative approaches in an engaging, interactive session.

Description: In this session, presenters will share the impacts of transition to IFRS 17 on equity and various KPIs across insurance companies (Life & P&C), as well as share some observations of what the IFRS 17 landscape looks like across different global regions. The session will conclude with lessons learned and expectations for emerging practices under IFRS 17 globally.

Description: Gain a high-level understanding on how long-duration targeted improvement (LDTI) impacts insurance products and earnings. Explore highlights on secondary impacts to companies due to additional complexity of LDTI, such as a need for a source of earnings analysis. Then dive into the details and hear an explanation on how earnings emergence differs for each type of life and annuity product impacted by LDTI. Finally, discuss the impact -to-earnings volatility under LDTI for each product type. Close the session by connecting how the investor story changes with all the impacts discussed during the session.You should walk away with a good understanding of LDTI earnings emergence, which is a topic that has very limited thought leadership available today.

Description: Join a discussion on the tax implications for direct writers ceding annuity blocks for both onshore and offshore reinsurance arrangements. Get an introduction to the tax consequences of the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are U.S.-based and not U.S. domiciled.

Description: IUL continues to be the strongest selling UL product. Companies have great profit/pricing expectations, but are those results being achieved? Learn about potential areas of underperformance for IUL including behavior related issues, hedging inefficiency, and mortality issues. The session will also discuss ways to monitor these risks and discuss different means to address potential issues of underperformance in hedging, pricing and in force earnings.

Description: In the time since the original proposal to move healthwriting companies from the blue blank to the orange blank, there have been several incremental updates to the blue blank by the NAIC Blanks Working Group to integrate portions of the orange blank into the blue blank. Meanwhile, the NAIC RBC Working Group has issued their proposal to change the health test for comment and appear to be moving forward with the proposal to revise the health test. This would obligate companies that write predominantly health business onto the orange blank rather than the blue blank, which they have historically used for reporting. Discover background of the revised health test, the incremental updates to the blue blank that have been implemented recently, additional incremental updates proposed for upcoming blue blanks, and the current status of the Health RBC Working Group proposal to revise the health test. Hear observations about companies that have opted to 'take the plunge' and move to the orange blank ahead of the revised health test as well as companies that have opted to remain on the blue blank and incrementally update as new requirements are integrated into the Blue blank. By attending the session, you will be able to: • Understand the context of the initiative to revise the NAIC health test. • Summarize the recent changes to the blue blank implemented by the Blanks Working Group that integrate portions of the orange blank into the blue blank. • Summarize the upcoming proposed changes to the blue blank by the Blanks Working Group that integrate additional portions of the orange blank into the blue blank. • Summarize the current status of the Health RBC Working Group proposal to revise the health test. • Provide industry perspective on companies that have opted to move to the orange blank ahead of the revised health test and companies that have opted to remain on the blue blank until the NAIC requires it.